Narrative Review of Patient Cancer Tissue–Derived Zebrafish Xenograft Models for Evaluating Drug Sensitivity as an Avatar Model for Clinical Application
Cancer Medicine · 2025-07 · 14 (13)
DOI: 10.1002/cam4.70942 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Medicine, online erschienen am 26.06.2025. Verfasst von Yusuke Sugino und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephro-Urologic Surgery and Andrology, Mie University Graduate School of Medicine, Tsu, Japan. Hauptthemen laut MEDLINE: Xenograft Model Antitumor Assays, Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
In the pursuit of optimal medical care, treatment selection based on the molecular analysis of genomes, transcriptomes, and proteomes has been explored; however, this approach relies on data from large patient groups, resulting in limited accuracy in predicting treatment efficacy. Diseases involve complex pathological networks, requiring treatments that target multiple key molecules in these networks. Drug screening using these networks, which cannot be achieved through a gene expression analysis alone, requires animal models. Zebrafish embryos have an immature immune system, allowing for a high engraftment rate of human cancer cells transplanted within 48 h after fertilization. Consequently, the time required for engraftment is also reduced. Less than 500 human cancer cells are required for transplantation, enabling the assessment of drug efficacy from clinical samples within approximately 1 week. The cost of raising zebrafish is low, drug efficacy can be evaluated using small amounts of drugs, and their use aligns closely with animal welfare standards. This review aims to discuss the technical aspects of evaluating drug efficacy using zebrafish patient cancer tissue–derived xenograft (zPDX) models and summarize previous studies using zPDX as an avatar model for personalized medicine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephro-Urologic Surgery and Andrology, Mie University Graduate School of Medicine, Tsu, Japan.
- Center for Medical Zebrafish Research, Mie University, Tsu, Japan.
- Department of Systems Pharmacology, Mie University Graduate School of Medicine, Tsu, Japan.
ORCID-Profile: Takumi Kageyama, Takahiro Inoue
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Sugino, Y., Bao, X., Kageyama, T., Sekito, S., Miyachi, S., Sasaki, T., Tanaka, T., & Inoue, T. (2025). Narrative Review of Patient Cancer Tissue–Derived Zebrafish Xenograft Models for Evaluating Drug Sensitivity as an Avatar Model for Clinical Application. Cancer Medicine, 14(13). https://doi.org/10.1002/cam4.70942
Vancouver
Sugino Y, Bao X, Kageyama T, Sekito S, Miyachi S, Sasaki T, et al. Narrative Review of Patient Cancer Tissue–Derived Zebrafish Xenograft Models for Evaluating Drug Sensitivity as an Avatar Model for Clinical Application. Cancer Medicine. 2025;14(13). doi:10.1002/cam4.70942
BibTeX
@article{Sugino2025,
author = {Sugino, Yusuke and Bao, Xin and Kageyama, Takumi and Sekito, Sho and Miyachi, Shiori and Sasaki, Takeshi and Tanaka, Toshio and Inoue, Takahiro},
title = {Narrative Review of Patient Cancer Tissue–Derived Zebrafish Xenograft Models for Evaluating Drug Sensitivity as an Avatar Model for Clinical Application},
journal = {Cancer Medicine},
year = {2025},
volume = {14},
number = {13},
doi = {10.1002/cam4.70942}
}
EUVIMED